2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine has been researched along with eritoran in 1 studies
Studies (2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine) | Trials (2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine) | Recent Studies (post-2010) (2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine) | Studies (eritoran) | Trials (eritoran) | Recent Studies (post-2010) (eritoran) |
---|---|---|---|---|---|
46 | 0 | 7 | 55 | 6 | 44 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Pearlman, E; Sun, Y | 1 |
1 other study(ies) available for 2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine and eritoran
Article | Year |
---|---|
Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564).
Topics: Animals; Apoptosis; Chemokine CXCL1; Cysteine; Disaccharides; Epithelium, Corneal; Eye Infections, Bacterial; Fluorescent Antibody Technique, Indirect; In Situ Nick-End Labeling; Keratitis; Lipopolysaccharides; Lipoproteins; Lymphocyte Antigen 96; Macrophages; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Sugar Phosphates; Toll-Like Receptors | 2009 |